The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
作者： Andreas Nüssler , Peter Neuhaus , Ulrich M. Zanger , Michel Eichelbaum , Thomas E. Mürdter
DOI: 10.1046/J.1365-2125.2002.01614.X
关键词:
摘要: … Z-3-OH-tam (droloxifene, 3-OH-tam), Z-4-OH-tam, Z-tam-N-oxide and Z-tamoxifen were gifts from Klinge Pharma GmbH (Munich, Germany). Z-α-OH-tam was obtained from Toronto …
core.ac.uk
sci-hub.se 参考文章(32)
Ulrich M. Zanger, Joachim Fischer, Sebastian Raimundo, Thomas Stüven, Bernd O. Evert, Matthias Schwab, Michel Eichelbaum, Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 Pharmacogenetics. ,vol. 11, pp. 573- 585 ,(2001) , 10.1097/00008571-200110000-00004
Thomas Lang, Kathrin Klein, Joachim Fischer, Andreas Nussler, Peter Neuhaus, Ute Hofmann, Michel Eichelbaum, Matthias Schwab, Ulrich Zanger, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. ,vol. 11, pp. 399- 415 ,(2001) , 10.1097/00008571-200107000-00004
O Gotoh, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry. ,vol. 267, pp. 83- 90 ,(1992) , 10.1016/S0021-9258(18)48462-1
Raymond McCague, Alison Seago, Aspects of metabolism of tamoxifen by rat liver microsomes: Identification of a new metabolite: E-1-[4-(2-dimethylaminoethoxy)-phenyl]-1, 2-diphenyl-1-buten-3-ol N-oxide Biochemical Pharmacology. ,vol. 35, pp. 827- 834 ,(1986) , 10.1016/0006-2952(86)90251-0
David Kupfer, Shangara S. Dehal, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Research. ,vol. 57, pp. 3402- 3406 ,(1997)
Victoria A. Eagling, John F. Tjia, David J. Back, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes British Journal of Clinical Pharmacology. ,vol. 45, pp. 107- 114 ,(1998) , 10.1046/J.1365-2125.1998.00679.X
D. J. Newton, R. W. Wang, A. Y. H. Lu, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition. ,vol. 23, pp. 154- 158 ,(1995)
Mats Hidestrand, Magnus Ingelman-Sundberg, Ümit Yasar, Gunnel Tybring, Marja-Liisa Dahl, Mikael Oscarson, Erik Eliasson, Role of CYP2C9 Polymorphism in Losartan Oxidation Drug Metabolism and Disposition. ,vol. 29, pp. 1051- 1056 ,(2001)
Jashvant D. Unadkat, Ji Ping Wang, Yi Wang, Dean Hickman, Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition. ,vol. 26, pp. 207- 215 ,(1998)
Ernst-Ulrich Griese, Ulrich M. Zanger, Ulrich Brudermanns, Andrea Gaedigk, Gerd Mikus, Klaus M??rike, Thomas St??ven, Michel Eichelbaum, Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population Pharmacogenetics. ,vol. 8, pp. 15- 26 ,(1998) , 10.1097/00008571-199802000-00003